Our results are concordant with reports that IGFBP2 is considered a prognostic factor for AML and ALL[26,27,29,30] and activates AKT[7] and suppresses PTEN expression[22,23] in certain solid cancer cells. This evidence concerns the gene IGFBP2 and acute myeloid leukemia.